Severe Acute Respiratory Syndrome (SARS) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the Severe Acute Respiratory Syndrome Coronavirus (SARS‑CoV). It first emerged in November 2002 in Guangdong Province, China, and spread to 26 countries, resulting in a worldwide outbreak in 2003. The disease is characterized by fever, cough, and progressive pneumonia that can become life‑threatening.

• Who it affects: Anyone can be infected, but the highest attack rates have been observed in adults aged 20–60 years. Health‑care workers were disproportionately affected because they were repeatedly exposed to infected patients.
• Prevalence: The WHO recorded 8,098 probable cases and 774 deaths (case‑fatality rate ≈ 9.6 %) during the 2002‑2004 outbreak. Since 2004, sporadic laboratory‑confirmed cases have occurred, most notably a 2012 “SARS‑like” coronavirus (MERS‑CoV) and isolated SARS‑CoV re‑emergences, but no large‑scale epidemic has been reported.
• Transmission: Primarily through respiratory droplets, direct contact with contaminated surfaces, and, in some cases, aerosolized particles during medical procedures.

Understanding SARS remains important because the same family of coronaviruses (Betacoronaviridae) includes the agents that cause COVID‑19, MERS, and future emerging respiratory threats.

Symptoms

SARS typically has an incubation period of 2–10 days (median ≈ 4–5 days). Symptoms evolve in three phases: prodromal, respiratory, and systemic.

• Fever (≥ 38 °C/100.4 °F) – present in > 90 % of cases and often the first sign.
• Chills & rigors – common during the febrile spike.
• Headache – may be mild to severe.
• Myalgia (muscle aches) – especially in the back and limbs.
• Dry cough – initially non‑productive; can become productive as pneumonia develops.
• Dyspnea (shortness of breath) – usually appears 5–7 days after symptom onset and signals progression to lower‑respiratory involvement.
• Sore throat – less common than in influenza.
• Rhinorrhea (runny nose) & nasal congestion – reported in a minority.
• Gastrointestinal symptoms – nausea, vomiting, diarrhea (≈ 20 % of patients).
• Chest pain or tightness – may accompany severe pneumonia.
• Fatigue & malaise – can be profound, persisting weeks after respiratory recovery.
• Hypoxia – oxygen saturation < 92 % on room air is a red‑flag sign.

Symptoms can mimic influenza or other viral pneumonias, which is why laboratory confirmation is essential.

Causes and Risk Factors

Cause

SARS is caused by infection with SARS‑CoV, a single‑stranded RNA virus belonging to the genus Betacoronavirus. The virus attaches to host cells via the ACE2 (angiotensin‑converting enzyme 2) receptor, which is abundant on respiratory epithelium, endothelial cells, and some gastrointestinal cells.

Risk Factors

• Close contact with a confirmed case – especially prolonged face‑to‑face exposure or caring for an ill person.
• Health‑care occupation – inadequate personal protective equipment (PPE) was a major driver in the 2003 outbreak.
• Age – older adults (> 60 years) have higher mortality.
• Underlying chronic illnesses – e.g., cardiovascular disease, diabetes, chronic lung disease, or immunosuppression increase risk of severe disease.
• Smoking – impairs mucociliary clearance and may up‑regulate ACE2 expression.

Diagnosis

Diagnosis combines epidemiologic clues, clinical presentation, imaging, and laboratory testing.

Step‑wise Approach

1. History & Physical Exam – recent travel to an area with known SARS activity, contact with a probable case, and classic symptoms raise suspicion.
2. Chest Imaging –
   • Chest X‑ray: early infiltrates may be subtle; later shows patchy, bilateral consolidations.
   • High‑resolution CT (HRCT): ground‑glass opacities, peripheral consolidation, and “crazy‑paving” pattern are typical and more sensitive than X‑ray.
3. Laboratory Tests –
   • Real‑time reverse transcription polymerase chain reaction (RT‑PCR) on nasopharyngeal or sputum specimens is the gold standard for detecting viral RNA.
   • Serology (IgM/IgG) can confirm infection after 2‑3 weeks but is less useful for acute management.
   • Complete blood count often reveals lymphopenia (low lymphocyte count) and mild thrombocytopenia.
   • Elevated inflammatory markers (CRP, LDH, ferritin) correlate with disease severity.
4. Exclusion of other pathogens – influenza PCR, RSV testing, and bacterial cultures are performed to rule out co‑infection.

International guidelines (WHO, CDC) recommend isolation of suspected cases until two consecutive negative RT‑PCR results are obtained ≥ 24 hours apart.

Treatment Options

There is no specific antiviral approved for SARS, and care is largely supportive. Treatment strategies are categorized into pharmacologic, procedural, and lifestyle measures.

Pharmacologic Interventions

• Supportive care – antipyretics (acetaminophen or ibuprofen) for fever, analgesics for pain, and adequate hydration.
• Antivirals (investigational) – During the 2003 outbreak, agents such as ribavirin, lopinavir/ritonavir, and interferon‑α were used empirically, but controlled trials did not demonstrate clear benefit. Current research continues to evaluate remdesivir and monoclonal antibodies for related coronaviruses.
• Corticosteroids – High‑dose steroids were administered in severe cases to dampen the inflammatory “cytokine storm,” yet meta‑analyses showed mixed outcomes and increased risk of secondary infections. Use is now reserved for selected patients under specialist guidance.
• Antibiotics – Broad‑spectrum antibiotics are given only if bacterial superinfection is suspected, as routine use adds no benefit and promotes resistance.

Procedural and Respiratory Support

• Oxygen therapy – Nasal cannula, face mask, or high‑flow nasal oxygen to maintain SpO₂ ≥ 94 %.
• Non‑invasive ventilation (NIV) – CPAP/BiPAP may be tried in stable patients but carries aerosol‑generation risk; appropriate isolation and PPE are mandatory.
• Mechanical ventilation – Indicated for respiratory failure (PaO₂/FiO₂ < 200 mmHg). Lung‑protective ventilation (tidal volume 6 mL/kg predicted body weight) reduces ventilator‑induced injury.
• Extracorporeal membrane oxygenation (ECMO) – Considered for refractory hypoxemia when conventional ventilation fails.

Lifestyle & Supportive Measures

• Rest and gradual return to activity once afebrile for ≥ 48 hours.
• Nutrition: high‑protein, calorie‑dense diet to counteract catabolism.
• Smoking cessation – improves mucociliary clearance and oxygenation.
• Psychological support – isolation can cause anxiety and depression; counseling or tele‑health services are valuable.

Living with Severe Acute Respiratory Syndrome (SARS)

Although outbreaks are rare, individuals who have recovered from SARS may face lingering effects. The following tips help manage daily life and reduce the risk of relapse or complications.

• Monitor respiratory health – Keep a symptom diary; seek care promptly if cough, shortness of breath, or fever recurs.
• Pulmonary rehabilitation – Breathing exercises (diaphragmatic breathing, pursed‑lip breathing) improve lung capacity.
• Vaccinations – Stay up‑to‑date with influenza and COVID‑19 vaccines; they lower the chance of co‑infection that can aggravate lung injury.
• Regular medical follow‑up – Baseline chest X‑ray or CT is often ordered 3 months post‑recovery, then as clinically indicated.
• Physical activity – Start with low‑impact activities (walking, stretching) and progress under physician guidance.
• Stress management – Mindfulness, yoga, or counseling help mitigate post‑viral fatigue and mental health sequelae.
• Work accommodations – If you are a health‑care worker or have a job with high exposure risk, discuss reassignment or enhanced protective measures with your employer.

Prevention

Because SARS spreads primarily through droplets and close contact, infection control is the cornerstone of prevention.

1. Hand hygiene – Wash hands with soap and water for at least 20 seconds or use an alcohol‑based hand rub (≥ 60 % ethanol).
2. Respiratory etiquette – Cover coughs and sneezes with a tissue or elbow; discard tissues immediately.
3. Personal protective equipment (PPE) –
   • Medical masks (surgical or N95) for health‑care settings.
   • Eye protection (goggles or face shield) when within 1 meter of a patient.
   • Gloves and gowns when dealing with bodily fluids.
4. Environmental cleaning – Disinfect high‑touch surfaces (doorknobs, keyboards, medical equipment) with EPA‑registered virucidal agents at least twice daily.
5. Isolation of suspected cases – Private rooms with negative‑pressure ventilation; limit visitors.
6. Travel advisories – Follow WHO and CDC guidance on regions with active SARS transmission.
7. Vaccination research – While no licensed SARS vaccine exists yet, participation in clinical trials contributes to broader coronavirus preparedness.

Complications

If SARS is not promptly recognized and treated, it can lead to serious and potentially fatal complications.

• Acute respiratory distress syndrome (ARDS) – Severe hypoxemia requiring mechanical ventilation.
• Secondary bacterial pneumonia – Often caused by *Staphylococcus aureus* or *Streptococcus pneumoniae*.
• Cardiovascular events – Myocarditis, arrhythmias, and acute coronary syndrome have been reported.
• Multi‑organ failure – Kidney injury, hepatic dysfunction, and coagulopathy can develop during the cytokine‑storm phase.
• Long‑term pulmonary fibrosis – Up to 30 % of survivors show residual scarring on CT, leading to reduced lung capacity.
• Neuropsychological sequelae – Post‑traumatic stress disorder (PTSD), depression, and chronic fatigue are documented in survivors of the 2003 outbreak.

When to Seek Emergency Care

References

1. World Health Organization. SARS: How it Started, How it Ended, How it Could Return. WHO Press, 2004.
2. Centers for Disease Control and Prevention. Severe Acute Respiratory Syndrome (SARS). https://www.cdc.gov/sars/, accessed April 2026.
3. Mayo Clinic. SARS (Severe Acute Respiratory Syndrome). https://www.mayoclinic.org/diseases‑conditions/sars, accessed April 2026.
4. Cleveland Clinic. SARS: Symptoms, Diagnosis, and Treatment. https://my.clevelandclinic.org/health/diseases/22358-sars, accessed April 2026.
5. Ng, K. et al. “Clinical outcomes of patients with SARS.” *The Lancet*, 2004; 363: 1718‑1725.
6. Lee, N. et al. “Long‑term sequelae of SARS survivors.” *Chest*, 2006; 129(5): 1330‑1336.
7. National Institutes of Health. Coronavirus Disease 2019 (COVID‑19) Treatment Guidelines. Section on SARS‑CoV; 2023 update.

```